PURPOSE: Malignant high-grade gliomas are the most common secondary neoplasms in children cured of acute lymphoblastic leukaemia (ALL). Although many predisposing factors exist (including systemic or intrathecal chemotherapy, young age, brain infiltration and genetic predispositions), cranial irradiation appears to be the strongest one. METHODS: Three cases of secondary high-grade gliomas (two multiform glioblastomas, grade IV; one anaplastic astrocytoma, grade III) developed in ALL survivors (F-M, 1:2) 3 to 6.3 years after stopping ALL therapy according to BFM-90 trial. RESULTS: All tumours were supratentorial, contrast-enhancing, space-occupying, highly advanced and aggressive. Possible risk factors and current therapeutic options for paediatric ALL and malignant gliomas are reviewed and discussed. CONCLUSIONS: Prognosis in secondary malignant gliomas in children is poor (overall survival of 5, 10 and 19 months) despite intense therapy. Thus, protocols for paediatric ALL reduce prophylactic cranial irradiation in favour of intrathecal and intravenous high-dose MTX. Nevertheless, ALL survivors must undergo systematic, long-term surveillance for early detection of intracranial neoplasms.
PURPOSE: Malignant high-grade gliomas are the most common secondary neoplasms in children cured of acute lymphoblastic leukaemia (ALL). Although many predisposing factors exist (including systemic or intrathecal chemotherapy, young age, brain infiltration and genetic predispositions), cranial irradiation appears to be the strongest one. METHODS: Three cases of secondary high-grade gliomas (two multiform glioblastomas, grade IV; one anaplastic astrocytoma, grade III) developed in ALL survivors (F-M, 1:2) 3 to 6.3 years after stopping ALL therapy according to BFM-90 trial. RESULTS: All tumours were supratentorial, contrast-enhancing, space-occupying, highly advanced and aggressive. Possible risk factors and current therapeutic options for paediatric ALL and malignant gliomas are reviewed and discussed. CONCLUSIONS: Prognosis in secondary malignant gliomas in children is poor (overall survival of 5, 10 and 19 months) despite intense therapy. Thus, protocols for paediatric ALL reduce prophylactic cranial irradiation in favour of intrathecal and intravenous high-dose MTX. Nevertheless, ALL survivors must undergo systematic, long-term surveillance for early detection of intracranial neoplasms.
Authors: C A Felix; M M Nau; T Takahashi; T Mitsudomi; I Chiba; D G Poplack; G H Reaman; D E Cole; J J Letterio; J Whang-Peng Journal: J Clin Invest Date: 1992-02 Impact factor: 14.808
Authors: Stephanie E Combs; Sybille Gutwein; Daniela Schulz-Ertner; Michael van Kampen; Christoph Thilmann; Lutz Edler; Michael M Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2005-06 Impact factor: 3.621
Authors: M V Relling; J E Rubnitz; G K Rivera; J M Boyett; M L Hancock; C A Felix; L E Kun; A W Walter; W E Evans; C H Pui Journal: Lancet Date: 1999-07-03 Impact factor: 79.321
Authors: Brenda J Spiegler; Kimberly Kennedy; Ronnen Maze; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler; Paul C Nathan Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: A W Walter; M L Hancock; C H Pui; M M Hudson; J S Ochs; G K Rivera; C B Pratt; J M Boyett; L E Kun Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: Deborah P Waber; Lewis B Silverman; Lori Catania; William Mautz; Montse Rue; Richard D Gelber; Donna E Levy; Meredith A Goldwasser; Heather Adams; Annie Dufresne; Victoria Metzger; Ivonne Romero; Nancy J Tarbell; Virginia Kimball Dalton; Stephen E Sallan Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: J Elexpuru-Camiruaga; N Buxton; V Kandula; P S Dias; D Campbell; J McIntosh; J Broome; P Jones; A Inskip; J Alldersea Journal: Cancer Res Date: 1995-10-01 Impact factor: 12.701